Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Radiotherapy plays an integral role in cancer treatment. Approximately 60% of cancer patients will receive radiotherapy at some point in their treatment. A major improvement in patient outcomes occurs with the use of combined chemotherapy and radiotherapy. The combination of targeted biological agents with radiotherapy is the latest cutting-edge extension in cancer therapy for radiation oncologists. Combining Targeted Biological Agents with Radiotherapy: Current Status and Future Directions is an overview of the current state of clinical and pre-clinical research in combining radiotherapy w

Cancer --- Combined modality therapy. --- Growth factors --- Cell growth factors --- Cellular growth factors --- Growth peptides --- Growth promoting substances --- Growth substances --- Peptide growth factors --- Peptide regulatory factors --- Polypeptide growth factors --- Cytokines --- Peptides --- Combined modality treatment --- Multi-modal therapy --- Multimodal therapy --- Multimodal treatment --- Therapeutics --- Radiotherapy. --- Receptors. --- Treatment

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Combined Modality Therapy. --- Hyperthermia, Induced. --- Neoplasms --- Induced Hyperthermia --- Therapeutic Hyperthermia --- Therapy, Fever --- Fever Therapy --- Hyperthermia, Local --- Hyperthermia, Therapeutic --- Thermotherapy --- Local Hyperthermia --- Fever --- Hot Temperature --- Multimodal Treatment --- Therapy, Combined Modality --- Combined Modality Therapies --- Modality Therapies, Combined --- Modality Therapy, Combined --- Multimodal Treatments --- Therapies, Combined Modality --- Treatment, Multimodal --- Treatments, Multimodal --- therapy. --- Hyperthermic Intraperitoneal Chemotherapy --- Chemotherapy, Hyperthermic Intraperitoneal --- Hyperthermic Intraperitoneal Chemotherapies --- Intraperitoneal Chemotherapy, Hyperthermic --- Cancer --- Evaluation --- Congresses --- Adjuvant treatment --- Hyperthermia --- Combined Modality Therapy --- Hyperthermia, Induced --- therapy --- HYPERTHERMIA, INDUCED --- NEOPLASMS --- xxx

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Recent decades have seen remarkable advances in the treatment of upper gastrointestinal malignancies, i.e., adenocarcinoma and squamous cell carcinoma as well as gastrointestinal stromal and other rare tumors of the esophagus and stomach. While, historically, surgical resection has been the sole treatment for these tumors, multimodal therapies have meanwhile proven their efficacy. At present, pre- and postoperative chemotherapy and radiotherapy, targeted drug therapy, and stage-specific surgical approaches are all indispensable cornerstones of an individualized treatment for upper gastrointestinal malignancies. With such multimodal treatment, better outcomes comprising improved quality of life and prolonged survival have been achieved for patients. However, for many tumor entities and stages, the ideal combination and sequence of treatments is still being evaluated in clinical trials. Moreover, the value of novel approaches such as immunotherapy or robotic surgery remains a matter of research. In this Special Issue of Cancers, up-to-date original research, short communications, and comprehensive review articles on all modalities playing a role in the treatment of upper gastrointestinal malignancies have been published.

Public health & preventive medicine --- gastric cancer --- gastrectomy --- complications --- outcome --- survival --- lymph node ratio --- neoadjuvant chemotherapy --- conversion surgery --- cancer dormancy --- nuclear receptor NR2F1 --- clinical pathways --- gastric surgery --- oncological gastrectomy --- quality of care --- outcomes --- standardization --- adjuvant therapy --- gastrointestinal tract --- genetic diagnosis --- radiosensitivity --- mortality --- failure to rescue --- immunotherapy --- genetics --- esophageal cancer --- multidisciplinary --- gastric/gastroesophageal cancer --- perioperative chemotherapy --- overall survival --- relapse-free survival --- skeletal muscle index --- esophagectomy --- nutritional status --- sarcopenia --- esophageal anastomosis --- minimally invasive surgery --- induction chemotherapy --- chemo-radiotherapy --- neoadjuvant treatment --- esophageal squamous cell carcinoma --- multimodal treatment --- neoadjuvant chemoradiotherapy --- definitive chemoradiotherapy --- Lauren histotype --- gastrointestinal stromal tumor --- neuroendocrine tumor --- MALT lymphoma --- mucosal resection --- submucosal dissection --- GIST --- stomach --- neoadjuvant therapy --- imatinib --- organ preservation --- squamous cell esophageal cancer --- gastro-esophageal reflux disease --- Barrett's esophagus --- early adenocarcinoma of esophagus --- endoscopic submucosal dissection --- endoscopic mucosal resection --- gastric cancer --- gastrectomy --- complications --- outcome --- survival --- lymph node ratio --- neoadjuvant chemotherapy --- conversion surgery --- cancer dormancy --- nuclear receptor NR2F1 --- clinical pathways --- gastric surgery --- oncological gastrectomy --- quality of care --- outcomes --- standardization --- adjuvant therapy --- gastrointestinal tract --- genetic diagnosis --- radiosensitivity --- mortality --- failure to rescue --- immunotherapy --- genetics --- esophageal cancer --- multidisciplinary --- gastric/gastroesophageal cancer --- perioperative chemotherapy --- overall survival --- relapse-free survival --- skeletal muscle index --- esophagectomy --- nutritional status --- sarcopenia --- esophageal anastomosis --- minimally invasive surgery --- induction chemotherapy --- chemo-radiotherapy --- neoadjuvant treatment --- esophageal squamous cell carcinoma --- multimodal treatment --- neoadjuvant chemoradiotherapy --- definitive chemoradiotherapy --- Lauren histotype --- gastrointestinal stromal tumor --- neuroendocrine tumor --- MALT lymphoma --- mucosal resection --- submucosal dissection --- GIST --- stomach --- neoadjuvant therapy --- imatinib --- organ preservation --- squamous cell esophageal cancer --- gastro-esophageal reflux disease --- Barrett's esophagus --- early adenocarcinoma of esophagus --- endoscopic submucosal dissection --- endoscopic mucosal resection

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Conduct disorders in children --- Conduct disorders in adolescence --- Antisocial personality disorders --- Family psychotherapy. --- Comportement, Troubles du, chez l'enfant --- Comportement, Troubles du, chez l'adolescent --- Personnalité sociopathologique --- Thérapie familiale --- Treatment. --- Traitement --- Combined modality therapy --- Family psychotherapy --- Treatment --- Combined modality therapy. --- Social Behavior Disorders --- Combined Modality Therapy --- Community Mental Health Services. --- Family Therapy --- Klinische psychologie --- Ontwikkelingspsychologie --- in infancy & childhood. --- methods. --- in adolescence. --- therapy. --- psychotherapie --- speciale problemen --- psychotherapie. --- speciale problemen. --- Personnalité sociopathologique --- Thérapie familiale --- Family group therapy --- Family therapy --- Families --- Group psychotherapy --- Marriage counseling --- Acting-out (Child psychiatry) --- Antisocial personality disorders in children --- CD (Child psychiatry) --- Child conduct disorders --- Disturbance of conduct (Child psychiatry) --- Misconduct (Child psychiatry) --- Behavior disorders in children --- Adolescent psychopathology --- Combined modality treatment --- Multi-modal therapy --- Multimodal therapy --- Multimodal treatment --- Therapeutics --- Psychopathic personality --- Sociopathic personality --- Personality disorders --- Health and hygiene --- Conduct disorders in children - Treatment --- Conduct disorders in adolescence - Treatment --- Antisocial personality disorders - Treatment

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Recent decades have seen remarkable advances in the treatment of upper gastrointestinal malignancies, i.e., adenocarcinoma and squamous cell carcinoma as well as gastrointestinal stromal and other rare tumors of the esophagus and stomach. While, historically, surgical resection has been the sole treatment for these tumors, multimodal therapies have meanwhile proven their efficacy. At present, pre- and postoperative chemotherapy and radiotherapy, targeted drug therapy, and stage-specific surgical approaches are all indispensable cornerstones of an individualized treatment for upper gastrointestinal malignancies. With such multimodal treatment, better outcomes comprising improved quality of life and prolonged survival have been achieved for patients. However, for many tumor entities and stages, the ideal combination and sequence of treatments is still being evaluated in clinical trials. Moreover, the value of novel approaches such as immunotherapy or robotic surgery remains a matter of research. In this Special Issue of Cancers, up-to-date original research, short communications, and comprehensive review articles on all modalities playing a role in the treatment of upper gastrointestinal malignancies have been published.

gastric cancer --- gastrectomy --- complications --- outcome --- survival --- lymph node ratio --- neoadjuvant chemotherapy --- conversion surgery --- cancer dormancy --- nuclear receptor NR2F1 --- clinical pathways --- gastric surgery --- oncological gastrectomy --- quality of care --- outcomes --- standardization --- adjuvant therapy --- gastrointestinal tract --- genetic diagnosis --- radiosensitivity --- mortality --- failure to rescue --- immunotherapy --- genetics --- esophageal cancer --- multidisciplinary --- gastric/gastroesophageal cancer --- perioperative chemotherapy --- overall survival --- relapse-free survival --- skeletal muscle index --- esophagectomy --- nutritional status --- sarcopenia --- esophageal anastomosis --- minimally invasive surgery --- induction chemotherapy --- chemo-radiotherapy --- neoadjuvant treatment --- esophageal squamous cell carcinoma --- multimodal treatment --- neoadjuvant chemoradiotherapy --- definitive chemoradiotherapy --- Lauren histotype --- gastrointestinal stromal tumor --- neuroendocrine tumor --- MALT lymphoma --- mucosal resection --- submucosal dissection --- GIST --- stomach --- neoadjuvant therapy --- imatinib --- organ preservation --- squamous cell esophageal cancer --- gastro-esophageal reflux disease --- Barrett’s esophagus --- early adenocarcinoma of esophagus --- endoscopic submucosal dissection --- endoscopic mucosal resection --- n/a --- Barrett's esophagus